Metronidazole is under clinical development by Saptalis Pharmaceuticals and currently in Pre-Registration for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Pre-Registration drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Metronidazole’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Metronidazole (ATI-1501) is under development for the treatment of Clostridium difficile infections. The drug candidate is a proprietary taste-masked liquid suspension reformulation of metronidazole. It is administered orally. Metronidazole acts by targeting DNA.
Saptalis Pharmaceuticals overview
Saptalis Pharmaceuticals, LLC, a pharmaceutical company that develops complex generics and difficult to formulate dosage forms. The company is headquartered in United States.
For a complete picture of Metronidazole’s drug-specific PTSR and LoA scores, buy the report here.